New Delhi, October 29
The Supreme Court on Thursday sought response from the Centre on a PIL alleging that two medicines being used for treatment of Covid19 — Remdesivir and Favipiravir — didn’t have the necessary approvals.
A Bench headed by Chief Justice of India SA Bobde asked the Centre to respond in four weeks to the PIL filed by advocate ML Sharma petitioner who alleged that the WHO’s October 15 report said that these medicines were not designated officially as medicines for Covid treatment. The notice was only to make the Union Government aware of it, the Bench added.
Remdesivir and Favipiravir are antiviral drugs and their efficacy in treating Covid patients has been a matter of debate in the medical fraternity.
During the hearing of a petition seeking registration of an FIR by the CBI against 10 Indian pharmaceutical firms for manufacturing and selling these two medicines for treating Covid19 patients allegedly without valid licences, the top court had on September 16 said that there was an approval by the Union Government on use of Remdesivir and Favipiravir to treat Covid19. — TNS